SURPASS-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Archive — January 2026
Page 4 of 5 of this archive, newest first.
Independent analysis puts a SSA semaglutide lot at 97.6%, against 94.1% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The quiet end of the consolidator trading as Meridian Freight Partners
A proper account of an operation that existed, and of what closing it cost.
Leucine, isoleucine, and a difference no balance can measure
Stereochemical inversion changes the molecule, changes its biology, and changes its mass by exactly nothing.
Reading the retatrutide composition data without the press release
The trials measured mass. Nobody measured whether the participants got weaker.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a 40% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
Spain pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
What the trials monitored, and what that implies about routine practice
Every additional analyte raises the probability of a flagged result and lowers the average information content of the panel.
Date of analysis, date of manufacture, and the gap between them
A document is only as good as the chain that connects it to the material, and most chains here are two or three links longer than the paperwork admits.
Spain health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The one randomised trial that combined an incretin with supervised exercise
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
Holding a dose is a decision, not a failure
A dose held long enough stops being a pause and becomes a maintenance decision. That transition is rarely made explicitly.
What twenty companies say about storage, and what they have measured
What would make a difference is not a regulator. It is three lines on a certificate, all of which are already known to whoever wrote it.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
A supplier suspends shipping to Canada after 9 consecutive customs detentions
The route did not close because of a rule about peptides.
The online reseller trading as Adamant Research Supply enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
The ceiling is a tolerability finding, not an efficacy one
Where the curve flattens, what flattens with it, and what does not.
A supplier suspends shipping to South Africa after 8 consecutive customs detentions
The route did not close because of a rule about peptides.
Homopeptide declines, for the 4th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Saudi Arabia declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Sending the same vial twice, under two names
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
A reference interval is not a target, and a result outside one is not a diagnosis
A twelve-analyte panel in a perfectly healthy person has roughly even odds of producing at least one flagged result.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
SURPASS-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Halvard & Pike Apothecary of Portland, Maine enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
What the four services actually offer, test by test
A compendial sterility test takes fourteen days of incubation and consumes the containers tested. That timescale is incompatible with the business model that made…
A reference interval is not a target, and a result outside one is not a diagnosis
The arithmetic of the reference change value, worked for the analytes that matter here.
Argentina pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Calder Vale Peptides of Skipton closes after 4 years
A proper account of an operation that existed, and of what closing it cost.
Two-thirds back: the extension nobody expected to be the headline
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Six words a verification badge would need to mean anything
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
The 20-day notice: how a compounding wind-down works in Saudi Arabia
The document is four pages. Three of them are about dates.